Semaglutide pretreatment significantly protected rat livers from 5-fluorouracil chemotherapy damage by reducing inflammation, oxidative stress, and cell death while enhancing the cellular cleanup process of damaged mitochondria.
Chloroquine abolished protectionWhen the autophagy inhibitor chloroquine was added alongside semaglutide, the liver-protective effects disappeared — proving that enhanced mitophagy (cellular cleanup of damaged mitochondria) is essential to how semaglutide protects the liver.
What the researchers found
5-FU administration caused marked increases in hepatic enzyme levels, oxidative stress markers (malondialdehyde), inflammatory markers (TNF-α, IL-6), and histological liver injury in rats.
Semaglutide pretreatment (0.3 mg/kg orally) effectively counteracted these harmful effects through multiple pathways: it suppressed the ROS/NF-κB/NLRP3 inflammasome inflammatory cascade, reduced oxidative stress (lowering MDA while increasing glutathione), decreased apoptosis (reducing caspase-3), and activated the pCREB/Nrf2/HO-1 antioxidant signaling pathway.
Critically, semaglutide enhanced PINK1/Parkin-mediated mitophagy — the process of removing damaged mitochondria. When chloroquine (an autophagy inhibitor) was co-administered with semaglutide, the protective effects were abolished, confirming that mitophagy enhancement is a key mechanism of semaglutide's hepatoprotective action.
Why it matters
Chemotherapy-induced liver toxicity is a significant clinical problem that can force dose reductions or treatment discontinuation in cancer patients. Finding a drug that can protect the liver during chemotherapy — without interfering with the cancer-killing effects — would be extremely valuable. Semaglutide is already widely prescribed for other conditions, so if its hepatoprotective effects translate to humans, it could be repurposed relatively quickly as a supportive care agent during chemotherapy.
How the study worked
Sprague-Dawley rats were divided into five groups: control (saline), 5-FU alone (150 mg/kg IP), semaglutide (0.3 mg/kg oral) + 5-FU, semaglutide + 5-FU + chloroquine (10 mg/kg IP, autophagy inhibitor), and 5-FU + chloroquine. Liver damage was assessed through hepatic enzyme levels, oxidative stress markers (MDA, glutathione), inflammatory markers (TNF-α, IL-6), apoptosis markers (caspase-3), and histological examination. Molecular pathways were evaluated including NF-κB/NLRP3 inflammasome, PINK1/Parkin mitophagy, and pCREB/Nrf2/HO-1 signaling.
What this study cannot tell us
This is an animal study in rats using a single chemotherapy agent (5-FU) at a specific dose. The results may not translate directly to humans or to other chemotherapy drugs. The study did not assess whether semaglutide affects the anti-tumor efficacy of 5-FU — a critical question for clinical application. Semaglutide was given as pretreatment, and its protective effect when given after chemotherapy initiation is unknown. The study used a single semaglutide dose, so dose-response relationships are not established. Long-term effects and safety of combining GLP-1 agonists with chemotherapy are not addressed.
How to read the evidence
This is a preclinical animal study with a well-designed experimental approach including appropriate controls and a mechanistic inhibitor (chloroquine) to confirm the proposed pathway. The evidence is strong for the rat model but preliminary for clinical translation.
When this study was published
Published in 2025, this is a very recent study contributing to the rapidly expanding body of evidence on semaglutide's protective effects beyond metabolic disease. Human studies would be the next logical step.
The bigger picture
The expanding universe of semaglutide benefits continues to grow beyond diabetes and obesity. This study adds liver protection during chemotherapy to the list, joining cardiovascular protection, kidney protection, and potential neurological benefits. The finding that GLP-1 receptor activation enhances mitophagy — cellular cleanup of damaged mitochondria — reveals a fundamental mechanism that could explain many of semaglutide's tissue-protective effects across different organs.
Questions still open
- Does semaglutide interfere with the anticancer effects of 5-FU or other chemotherapy drugs?
- Would semaglutide protect against liver toxicity from other hepatotoxic chemotherapy agents beyond 5-FU?
- Could GLP-1 receptor agonists become standard supportive care during chemotherapy for patients with diabetes or obesity who are already taking these drugs?
Common questions
What is mitophagy and why does it matter for liver protection?
Could semaglutide be given alongside chemotherapy in cancer patients?
Read the original research
Exploring novel protective role of semaglutide in 5-fluorouracil-induced hepatotoxicity: Insights into phosphorylated CREB, PINK1/Parkin-mediated mitophagy, and NF-κB/NLRP3 pathways.
The Journal of pharmacology and experimental therapeutics, 392(8), 103629
Citation
El Sayed, Nermein F; Baraka, Sara A; El-Mokadem, Bassant M; El Osaily, Heba H; Bishr, Abeer. (2025). Exploring novel protective role of semaglutide in 5-fluorouracil-induced hepatotoxicity: Insights into phosphorylated CREB, PINK1/Parkin-mediated mitophagy, and NF-κB/NLRP3 pathways.. The Journal of pharmacology and experimental therapeutics, 392(8), 103629. https://doi.org/10.1016/j.jpet.2025.103629